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Neural crest cells are a transient stem cell-like popu-
lation appearing during vertebrate embryonic devel-
opment. Generation of the cranial neural crest is
known to require a balanced combination of FGF
and BMP levels. However, it is poorly understood
how the functions of such growth factors are con-
trolled in the extracellular space. Anosmin is an extra-
cellularmatrixprotein implicated inFGFsignalingand
mutated in Kallmann syndrome. Here, we demon-
strate that anosmin is synthesized locally in the
cranial neural crest of chicken embryos and is essen-
tial for cranial neural crest formation. Anosmin upre-
gulates FGF8 and BMP5 gene expression; it also
enhances FGF8 activity while inhibiting BMP5 and
WNT3a signaling. Taken together, our data establish
that the matrix protein anosmin is required for cranial
neural crest formation, with functional modulation of
FGF, BMP, and WNT.
INTRODUCTION
Understanding how the constituents of cellular microenviron-
ments containing extracellular matrix (ECM) and secreted
regulatory factors are coordinated to promote specific tissue
differentiation is one of the major challenges in cell and develop-
mental biology. Recently, important roles of local ECM mole-
cules have been suggested in tissue/organ morphogenesis
and stem cell fate determination (Sakai et al., 2003; Wang
et al., 2008; Engler et al., 2006). The composition and stiffness
of the local microenvironment affect fate determination, differen-
tiation, proliferation, survival, polarity, and migration of cells
(reviewed in Hynes, 2009; Yamada andCukierman, 2007; Nelson
and Bissell, 2006). Furthermore, local interactions and matrix-
mediated presentation of secreted growth factors to cell surface
receptors are also important during embryonic development,
stem cell fate determination, and cancer (e.g., see reviews by
Hynes, 2009; Discher et al., 2009). Thus, it is important to under-
stand how growth factor cues that govern tissue differentiation
are coordinated by the microenvironment.
Neural crest cells appear transiently during embryonic devel-
opment, and they generate a variety of cells and tissues includ-Developing neurons, glia, and craniofacial bones and connective tissues
(Le Douarin and Kalcheim, 1999). The neural crest primordium
forms at the boundary of the epidermal ectoderm and neural
plate; it is specified by local growth factors such as fibroblast
growth factor (FGF), bone morphogenetic protein (BMP), and
Wingless/INT-related (WNT) during gastrulation (Basch et al.,
2006). Furthermore, it has been suggested that a balance
between the levels of FGF and BMP (an intermediate level of
the latter) is important for cranial neural crest generation (re-
viewed in Sauka-Spengler and Bronner-Fraser, 2008). Specifi-
cation and formation of the neural crest involves a variety of
transcription factors, including the paired box transcription
factor PAX7, zinc finger transcription factor SNAI2, forkhead
transcription factor FOXD3, and HMG box transcription factor
SOX9 (Basch et al., 2006; Nieto et al., 1994; Dottori et al.,
2001; Cheung and Briscoe, 2003). These transcription factors
are induced by growth factors, and they promote not only
neural crest specification/formation but also subsequent epithe-
lial-mesenchymal transition (EMT) and cell migration into the
embryonic body (reviewed in Sauka-Spengler and Bronner-
Fraser, 2008).
During neural crest cell development, ECM molecules such
as fibronectin, laminin, and collagen have been studied ex-
tensively for their roles in cell migration and differentiation
(reviewed in Henderson and Copp, 1997; Rogers et al., 1990).
Recent studies suggest that ECM molecules, as well as
growth factor antagonists, can be involved in achieving specific
tissue differentiation. For example, the olfactomedin family
has been identified as a new class of regulatory extracellular
proteins, with the olfactomedin family member Noelin-1
enhancing neural crest formation in chick development (Bare-
mbaum et al., 2000) and ONT1 involved in Xenopus dorsal-
ventral (DV) axis formation by controlling protein levels of
chordin, a BMP antagonist (Inomata et al., 2008). However, it
is poorly understood how ECM proteins might coordinate
functions of growth factors such as FGF, BMP, and WNT
during embryonic development. Consequently, we hypothe-
sized that ECM molecules might regulate cranial neural crest
formation by controlling functions of these growth factors in
local microenvironments.
In this study, we identified the ECM protein anosmin as a
molecule closely linked by both temporal and spatial mRNA
expression patterns with formation of the cranial neural crest.
Loss- and gain-of-function experiments using antisense mor-
pholino oligonucleotides (mo) or purified anosmin protein andmental Cell 23, 305–316, August 14, 2012 ª2012 Elsevier Inc. 305
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Figure 1. Identification of Anosmin Gene
Expression in NFs
(A) SNAI2 mRNA expression in NFs of chicken
embryo during neural crest formation (HH8). Scale
bar, 150 mm.
(B) Cross-section of cranial region of a HH8
embryo coimmunostained with SNAI2 and fibro-
nectin antibodies. NF (red rectangle) and NP (blue
arc) were dissected from HH8 embryos (80 to 114
embryos, n = 4), and total RNA was analyzed
using GeneChip chicken genome arrays (32,773
transcripts corresponding to >28,000 chicken
genes, Affymetrix). Scale bar, 150 mm.
(C) Gene expression profiles in NF and NP by mi-
croarray analysis. Cluster analysis was performed
using log2 ratios for NF and NP genes.
(D) Fold difference (NF/NP) of anosmin gene
expression compared with neural crest genes and
BMP family genes by quantitative PCR (qPCR).
Data are shown as means and SEM.
(E) Time-dependent change of anosmin gene
expression compared with SNAI2 and FOXD3
from HH4 to HH9 by qPCR (HH5 gene expression
is 1). Data are shown as means and SEM.
Developmental Cell
Role of Anosmin in Cranial Neural Crest Formationgrowth factors reveal that anosmin plays a critical role in cranial
neural crest formation. Using growth factor-specific luciferase
reporters, we show that anosmin specifically enhances FGF8
functions while inhibiting BMP5 and WNT3a. Based on these
findings, we propose that anosmin promotes cranial neural
crest formation by governing growth factor functions in avian
embryonic development.
RESULTS
Microarray Analysis Identifies the ECMProtein Anosmin
in the Neural Fold
During neurulation in chicken embryos, the cranial neural fold
(NF) is a unique structure formed at the boundary of the neural
plate and the epidermal ectoderm. The neural fold gives rise to
the cranial neural crest, which is characterized by expression
of SNAI2 messenger RNA (mRNA) and protein (Figures 1A and
1B). The ECM protein fibronectin is localized mainly in the base-
ment membrane and mesenchymal tissues rather than in the
neural fold (Figure 1B). We searched for an ECM protein that
was synthesized locally in the neural fold with the hypothesis
that this type of ECM protein might regulate neural crest forma-
tion. We analyzed gene expression profiles of the NF compared
to the ventral neural plate (NP; Figure 1B) from embryos at the
cranial neural crest formation stage (Hamburger & Hamilton
stage 8; HH8) using chicken genome microarray chips from
Affymetrix; the microarray data are deposited in GEO under
series accession number GSE38381.
We first validated the microarray data by searching for differ-
ential expression of known neural crest genes such as SNAI2,
FOXD3, and SOX9 compared with neural plate genes such as
SHH, chordin and NKX-6.1 (Figure 1C). We confirmed that the
neural fold differential gene expression profiles included a set
of 10 known neural crest genes with high differential expression
(Figure 1C). After this validation, we found that extracellular
matrix gene anosmin was prominent in the neural fold profiles
and displayed the highest fold difference (log2 ratio > 5.7;306 Developmental Cell 23, 305–316, August 14, 2012 ª2012 ElsevieFigure 1C) compared to other extracellular matrix genes (e.g.,
fibronectin, log2 ratio = +1.9, and laminin and collagen showed
no significant differences; data not shown). We confirmed the
differential gene expression of anosmin by reverse transcription
PCR (data not shown) and quantitative PCR (qPCR; Figure 1D).
Comparable to known neural crest regulatory genes, such as
SNAI2, FOXD3, SOX9, and BMP family genes, anosmin was
expressed more than 50 times higher in the neural fold than in
the neural plate by qPCR (Figure 1D), and the peak of anosmin
expression was at HH8 (Figure 1E). Human anosmin gene muta-
tions cause the X-linked form of Kallmann syndrome (KAL1;
Legouis et al., 1991) and result in anosmia and craniofacial
defects. It has recently been suggested that anosmin modulates
FGF signaling (Hu et al., 2009). However, it is poorly understood
how anosmin functions during embryonic development. This
study identifies functions of anosmin in cranial neural crest
development.
Anosmin Is Specifically Expressed in the Cranial
Neural Crest
We first characterized the spatial and temporal patterns of
craniofacial anosmin mRNA expression by in situ hybridization
(Figures 2A–2I) compared to the neural crest marker SNAI2
(Figures 2J and 2K). Anosmin mRNA expression first appeared
in the anterior neural ridge (ANR) at HH5+ (Figure 2B, arrow-
heads). At HH6-7+, its expression extended to more central
regions of cephalic neural fold (Figures 2C and 2D, arrowheads),
and by HH8 and 9, its expression was specifically and strongly
localized to the entire NF (Figure 2F, arrowheads). As determined
by serial sections, anosmin mRNA localization overlapped with
the dorsal zone of SNAI2 expression (Figures 2G and 2J, arrow-
heads), suggesting that the dorsal part of the cranial neural crest
and the ANR are the primary sources of anosmin. However,
during or after neurulation (just before the time of neural
crest cell emigration at HH9 to 9), anosmin mRNA expression
levels progressive decreased in the NFs (Figures 2I and 2E,
arrowheads).r Inc.
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Figure 2. Anosmin mRNA and Protein
Expression in NF
(A–K) AnosminmRNA expression by whole-mount
in situ hybridization. Weak anosmin expression is
detected in the ANR at HH5+ (B, indicated with
arrowheads), and then its expression expands
progressively from HH6 to HH8 to cover the NF,
as indicated with arrowheads in (C), (D), and (F).
By the time of neural crest migration, anosmin
expression is decreased (E, indicated with white
arrowheads). Anosmin, in (G) and (I), and SNAI2,
in (J) and (K), mRNA expression on a series of
serial sections by in situ hybridization. Anosmin
expression is colocalized with SNAI2 in NF at
HH8, indicated by arrowheads in (G) and (J), but
at HH9 anosmin expression begins to decrease
at the anterior/posterior midbrain region indicated
by arrowheads in (H), (I), and (K). Scale bar, 150 mm
in (A)–(F) and (H) and 50 mm in (G), (I), (J), and (K).
(L–S) Anosmin protein expression in the anterior
midbrain region (L, at the same level as the upper
arrowheads in H), posterior midbrain region (N),
and midbrain/hindbrain boundary region (P, same
level as lower arrowheads in H) of HH 9 embryo.
Before neural crest migration, anosmin is present
in the entire neural plate with highest expression
in the neural fold (L, indicated by arrowheads).
Arrowheads indicate anosmin expression in
cranial neural crest cells emigrating from cranial
neural tube (N). At the midbrain/hindbrain
boundary region, anosmin protein expression is
weaker compared with the anterior midbrain
regions (P, indicated by open arrowheads). As
a negative control, preimmune serum was used
on sections of HH9 embryos (R). Asterisk in (B)
indicates migratingmesenchymal cells of primitive
streak and presomitic mesoderm. Nuclei were
stained by DAPI, as shown in (M), (O), (Q), and (S).
Scale bar, 50 mm.
See also Figure S1.
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Role of Anosmin in Cranial Neural Crest FormationNext, we determined the localization of anosmin protein
using an affinity-purified polyclonal antibody against chicken
anosmin (Figures 2L, 2N, and 2P; Figure S1 available online).
We found that anosmin protein extended into the entire cranial
neural ectoderm but with highest expression in the neural fold
of the anterior midbrain (Figure 2L, arrowheads) and with
lower expression in the posterior midbrain (Figure 2P, open
arrowheads) before neural crest cell emigration. At the time
of neural crest cell migration, anosmin protein was also ex-
pressed in the neural crest cells (Figure 2N, arrowheads). As
previously reported by Hardelin et al. (1999), anosmin protein
was localized in basement membranes and interstitial spaces
of the ectoderm. This regional and transient expression of
anosmin mRNA and the presence of anosmin protein sug-
gested that anosmin could be involved in cranial neural crest
formation.Developmental Cell 23, 305–316Anosmin Is Needed for Cranial
Neural Crest Formation
To examine whether anosmin is required
for cranial neural crest formation, we
introduced antisense mo into the cranialectoderm of HH4+-5 embryos to inhibit new synthesis of
anosmin protein in NFs (see Experimental Procedures). After
introduction of mo, the embryos were cultured for 10–12 hr
until HH8-9. Compared with control-mo, anosmin-mo pro-
duced approximately 50% knockdown of anosmin protein in
NFs (Figures S2A–S2F). In control-mo-treated embryos,
SNAI2 mRNA was expressed normally in the neural crest
(Figures 3A and 3B). In contrast, SNAI2 expression was
substantially decreased in anosmin knockdown embryos
compared with controls (Figures 3B and 3D, 6 out of 6, arrow-
heads). We also examined the effects of anosmin knockdown
on other neural crest markers by qPCR (Figures 3I–3O).
qPCR confirmed the results for SNAI2, accompanied by
reductions of FOXD3, SOX9, and MSX1 (>50%; Figures 3J–
3L) in NF, while levels of expression of PAX7, TFAP2A, and
PAX6 were not changed (Figures 3M–3O). Because PAX7, August 14, 2012 ª2012 Elsevier Inc. 307
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Figure 3. Reducing Anosmin in the Neural
Fold Decreases SNAI2 but Not PAX7
Expression
(A–H) Electroporations of FITC-tagged control-
mo, in (A), (B), (E), and (F), or FITC-tagged anos-
min-mo, in (C), (D), (G), and (H), were performed
using HH4+-5 embryos, and the embryos were
cultured for 10–11 hr until HH8-9. Transfected
regions are visualized by FITC fluorescence over-
laid on brightfield images of live embryos in (A), (C),
(E), and (G). SNAI2 and PAX7 expression in the
head fold, in (B), (D), (F), and (H), are shown at
higher magnification corresponding to the boxed
areas of (A), (C), (E), and (G), respectively. In
anosmin-mo-treated embryos, SNAI2 expression
was decreased (D, indicated by arrowheads), but
PAX7 expression was not changed significantly
(H, indicated by arrowheads). Scale bar, 200 mm.
(I–O) Gene expression of neural fold genes by
qPCR. NFs of HH8 and HH9 control-mo- (each n =
3) or anosmin-mo-treated embryos (each n = 3)
were dissected, and total RNAwas used for qPCR.
SNAI2, FOXD3, SOX9, and MSX1 expression
levels were decreased in anosmin knockdown
neural fold in (I), (J), (K), and (L), while PAX7,
TFAP2A, and PAX6 expression did not change
significantly, as shown in (M), (N), and (O). Data are
shown as means and SEM. *p < 0.01.
See also Figure S2.
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Role of Anosmin in Cranial Neural Crest Formationgene expression is required for neural crest specification
during gastrulation (Basch et al., 2006), we confirmed the
qPCR results by whole-mount in situ hybridization (Figures
3E–3H) Compared with control-mo-treated embryos, PAX7
expression of anosmin-mo-treated embryos showed no sig-
nificant difference (Figures 3F and 3H, 5/5, arrowheads).
Apoptosis was not increased in anosmin-depleted embryos
(Figure S2G), and the decreased expression of SNAI2 and
FOXD3 was rescued by injection of exogenous anosmin
(Figures S2H and S2I). Combined with the anosmin gene
expression patterns, our findings suggest that anosmin is
needed for cranial neural crest formation rather than for initial
neural crest specification.
FGF8 and BMP5 Expression in NF Requires Anosmin
We hypothesized that anosmin might play regulatory roles
in vivo—particularly roles related to the proposed requirements
for FGF and an intermediate level of BMP in cranial neural
crest formation (reviewed in Sauka-Spengler and Bronner-308 Developmental Cell 23, 305–316, August 14, 2012 ª2012 Elsevier Inc.Fraser, 2008). We first examined whether
anosmin knockdownmight affect expres-
sion of either of these growth factors
during neural crest formation.
FGF8 is known to play an important
role in cranial neural crest formation
and head development (Litsiou et al.,
2005; Hong et al., 2008; Monsoro-Burq
et al., 2005). In chicken embryos, FGF8
is expressed strongly in the ANR and
in cranial neural crest (Bailey et al.,
2006; Figure 4B). We examined foraltered FGF8 expression in NFs of anosmin knockdown
embryos by whole-mount in situ hybridization. We found that
FGF8 expression was substantially decreased in the NF
compared with controls (Figure 4D, 4/4, arrowheads). We
quantified the decrease in FGF8 expression in neural folds of
anosmin-mo embryos by qPCR as >60%, compared to
controls (Figure 4E). These results suggest that FGF8 is
a gene downstream of anosmin required for cranial neural
crest formation.
We next examined for regulatory effects of anosmin on the
BMP family. Our gene expression profiles of NF identified high
differential expression of BMP4 and BMP5 mRNA (Figure 1C),
and this high expression was confirmed by qPCR (Figure 1D).
We used whole-mount in situ hybridization to characterize
the temporal and spatial expression pattern of BMP5 in cranial
neural crest (Figure S3). BMP5 expression was first detected
in cranial neural crest at HH7 (Figure S3A, arrowheads) after
SNAI2 expression appeared at HH6 (Endo et al., 2002; data
not shown); BMP5 was then strongly expressed in the cranial
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Figure 4. Anosmin Is Required for FGF8 and
BMP5 Expression in NF
(A–J) Electroporation of FITC-tagged control-mo
(A, B, F, and G) and FITC-tagged anosmin-mo (C,
D, H, and I) was performed using HH4+-5
embryos, and the embryos were cultured for 10-
11 hr until HH8-9. Transfected regions are shown
as FITC fluorescence overlaid on the brightfield
image of live embryos in (A), (C), (F), and (H). FGF8
and BMP5 expression in the head fold are shown
at higher magnification in (B), (D), (G), and (I),
corresponding to the boxed areas of (A), (C), (F),
and (H), respectively. Coincident with the qPCR
results (E and J), expression of FGF8 and BMP5
was decreased in anosmin-mo-treated embryos
(D and I, indicated by arrowheads). Gene expres-
sion of neural fold genes by qPCR is shown in (E
and J). NFs of HH8 and HH9 or HH9 embryos
treated with control-mo (each n = 3) or anosmin-
mo (n = 3) were dissected, and total RNAwas used
for qPCR. Expression of FGF8 and BMP5 were
decreased in anosmin knockdown neural fold
compared with controls. Data are shown as
means and SEM. Scale bar, 200 mm. *p < 0.001.
(K and L) Rescue of SNAI2 expression by FGF8 +
BMP5 in anosmin-mo treated embryos. Electro-
poration of FITC-tagged mo was performed at
HH4+-5, and 6.5 hr after electroporation, a mixture
of FGF8 (2 mg/ml) and BMP5 (10 mg/ml) proteins in
0.1% BSA/HBSS was injected into the right side
(red asterisk) of the cranial regions of HH7+-8
embryos. The embryos were cultured for another
5.5 hr until HH8-9, and SNAI2 expression was
examined by whole-mount in situ hybridization.
Compared with the internal control (left side),
SNAI2 expression was rescued on the right side
(K, indicated by arrowheads). SNAI2 expression in
NFs from the control or rescued sides were quan-
tified by ImageJ (L, each n = 4). Scale bar, 200 mm.
Data are shown as means and SEM. *p < 0.02.
See also Figure S3.
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Role of Anosmin in Cranial Neural Crest Formationneural crest at HH8-9 (Figures S3B–S3D, arrowheads). In
contrast, during cranial neural crest formation in chicken
embryos, expression of BMP2 and BMP4 was downregulated
in cranial neural crest (Endo et al., 2002; data not shown). These
results suggest that BMP5 is involved in cranial neural crest
formation but not in its initial specification. Although the function
of BMP5 in cranial neural crest formation has been not examined
in detail, as previously shown for induction of SNAI2 and MSX2
expression in chicken limb development (Zuzarte-Luı´s et al.,
2004), we also found that purified BMP5 protein upregulated/
enhanced neural crest gene MSX2 expression in NF and plate
(data not shown).
We found that BMP5 expression was clearly decreased in
anosmin-mo-treated neural folds by whole-mount in situ hybrid-
ization (Figure 4I, 3/3, arrowheads). We quantified the decreases
by qPCR (>50%, Figure 4J). In contrast, BMP4 expression was
not affected after anosmin knockdown according to qPCR
(data not shown). Taken together, our results suggest that
anosmin is required specifically for BMP5 gene expression, as
well as for other neural crest genes such as SNAI2, FOXD3,
and SOX9, but not BMP4.DevelopAnosmin Regulates Both FGF8 and BMP5 Required
for Cranial Neural Crest Formation
FGF and BMP signaling are known to be required for both cranial
neural crest specification and formation (Stuhlmiller and Garcı´a-
Castro, 2012; Mayor et al., 1997; Monsoro-Burq et al., 2003;
Endo et al., 2002), which we confirmed using dominant-negative
FGFR1 and noggin expression plasmids (data not shown). We
tested whether FGF8 and BMP5 are required for cranial neural
crest formation downstream of anosmin by a rescue experiment.
We assayed for SNAI2, the key marker of neural crest formation,
in anosmin-depleted embryos by injecting exogenous FGF8 or
BMP5. Although neither FGF8 nor BMP5 alone could rescue
(data not shown), very interestingly, injection of a certain combi-
nation of FGF8 (2 mg/ml) and BMP5 (10 mg/ml) proteins success-
fully restored normal expression of SNAI2 on the injected side
(Figure 4K, 8/10, arrowheads, and Figure 4L). In striking contrast,
injection of FGF8 plus BMP5 protein into normal embryos never
increased (and usually reduced) SNAI2 expression (Figures S3H
and S3H0, arrowheads). Moreover, bilateral injection into normal
embryos of FGF8 or BMP5 did not increase SNAI2 expression
by qPCR, and FGF8 plus BMP5 strongly inhibited rather thanmental Cell 23, 305–316, August 14, 2012 ª2012 Elsevier Inc. 309
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Figure 5. Purified Anosmin ProteinModulates FGF, BMP, andWNT Function by Direct Binding and Promotes Cranial Neural Crest Formation
(A–D) Anosmin binding to growth factors was examined by ELISA. (A-B)Wells were coated with tag-free purified recombinant anosmin protein or BSA as a control
(5.0 mg/well), then incubated with the indicated amounts of FGF8 or FGFR1. (C-D) Purified recombinant anosmin (2.5 mg/well) was added to 96-well plates coated
with various growth factors (0.5 mg/well) and BSA as a control. Bound anosmin was detected by anti-anosmin antibody (HL6157 or HL6308, see Supplemental
Experimental Procedures), and binding was measured at 450 nm. Data are shown as means and SEM.
(E and F) Western blots of coimmunoprecipitation by FGFR1 (E) or anosmin (F) antibodies stained for FGF8 or FGFR1.
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appropriate balance of growth factors (Figure S3I). These results
indicate that FGF8 and BMP5 are downstream of anosmin, and
all three molecules are required at appropriate levels for cranial
neural crest formation.
Anosmin Modulates FGF, BMP, and WNT Activities
We then explored whether anosmin could directly alter FGF,
BMP, and other growth factor activities beyond its function
documented earlier in promoting gene expression.We produced
recombinant chicken anosmin without any fusion protein tag
using mammalian cells (Figure S1; see Supplemental Experi-
mental Procedures). We first tested whether anosmin directly
binds to growth factors using ELISA (see Supplemental Experi-
mental Procedures). Anosmin bound strongly to FGF8, BMP5,
BMP7, and WNT3a (Figures 5A, 5C, and 5D), yet anosmin did
not directly bind to FGFR1, BMP2, or BMP4 (Figures 5B and
5C). In FGF8 ligand-binding assays (see Experimental Proce-
dures for details), we confirmed that anosmin bound to FGF8
but not to FGFR1 (Figure 5F). In addition, however, anosmin
increased the amount of FGF8 binding to FGFR1c in a dose-
dependent manner (Figure 5E). The reverse experiment
confirmed the conclusion that anosmin promotes FGF8-FGFR1
complex formation by direct binding to FGF8 (Figure 5F).
We next used a luciferase reporter assay system to test the
effects of anosmin on FGF, BMP, and WNT signaling using
mammalian cell lines stably expressing a promoter specific for
each growth factor (see Experimental Procedures). We first
confirmed that anosmin itself does not activate these assay
systems, with no detectable effects on FGF, BMP, and WNT
signaling in the absence of growth factors (data not shown).
However, we found that, when combined with these growth
factors, anosmin enhanced FGF8 activity more than 6-fold;
FGF2 and FGF4 showed lower enhancement of approximately
2-fold (Figures 5G and 5J). When compared with other ECM
molecules including fibronectin, laminin-III, and collagen I, anos-
min specifically enhanced FGF8 activity; these other ECM
proteins failed to enhance FGF8 activity (Figure 5G, compared
to anosmin shown in red). In striking contrast, anosmin either
inhibited or had no effect on BMP signaling; anosmin specifically
inhibited BMP5 and BMP7 compared to BMP2 and BMP4
activities (Figure 5K). Interestingly, other ECM proteins such as(G–K) Luciferase activity expressed as relative luciferase units (RLU), with activity o
mouse myoblasts (C2C12 cells) expressing an FGF-specific promoter construct
and FGF8—2 in (G and J)—while the ECM proteins fibronectin (3), laminin-III (4), an
expressing a BMP-specific promoter (BRA) was used (H and K). Anosmin inhibit
laminin-III enhanced BMP5 activity (H). For WNT activity, a C2C12 cell line exp
WNT3a activity, while other ECM proteins were without effect (I). Data are shown
(L)Western blotting of signalingmolecules downstream of GF receptors. Purified a
HH8+ embryos in ovo, and after 1–2 hr incubation at 38C, the entire cranial regi
blotting. GAPDH was the control.
(M and N) Immunostaining of phosphorylated p38 in anosmin bead-treated em
phosphorylated p38 positive neural crest (N). Scale bar, 50 mm.
(O–R00 0) Purified anosmin protein (red asterisk) and BSA as a control (black asteris
indicate the sites of injection in the anterior midbrain region, and asterisks in (Q
cultured for 5 hr and then examined for FGF8 and SNAI2 expression by whole-
expression levels at regions compared with internal control side and control BSA e
and 50 mm in (O0), (P0), (Q0, (R0), (R00), and (R00 0).
See also Figure S4.
Developfibronectin and laminin-III enhanced rather than inhibited
BMP5 activity (Figure 5H, anosmin shown in red). Finally, anos-
min inhibited WNT3a activity, whereas other ECM proteins had
no significant effect on its activity (Figure 5I, anosmin shown
in red). These results indicate that anosmin modulates FGF,
BMP and WNT activities. Specifically, anosmin enhances FGF8
activity while inhibiting BMP5, BMP7, and WNT3a activity.
Combined with ELISA assays and coimmunoprecipitation
results, these results suggest that anosmin can function mecha-
nistically to control specific extracellular growth factor activities
through direct binding interactions to each of these molecules.
Exogenous Anosmin Promotes Phosphorylation
of p38 In Vivo
We next examined whether anosmin can control downstream
signaling molecules such as p38 and ERK1/2 MAP kinases or
SMAD in vivo. Within 1–2 hr, p38 phosphorylation and ERK1/2
were enhanced 2.5 times and 2.2 times, respectively, while
SMAD phosphorylation was inhibited 0.7 times by purified anos-
min (1.5 mg/ml) in vivo (Figure 5L; Figure S4A). We confirmed the
western blotting evidence for increased p38 phosphorylation
by immunostaining. Normally, p38 is activated throughout the
entire neural plate (data not shown). While control BSA beads
had no effect on p38 phosphorylation, anosmin-soaked beads
enhanced p38 phosphorylation in the cells surrounding the
beads within 1–2 hr in vivo (21/23; Figure 5M, arrowheads).
Moreover, we observed that p38-positive neural fold was
expanded by this exogenous anosmin in forebrain (Figure 5N;
Figures S4B and S4C, arrowheads, 7/9), whereas already estab-
lished midbrain neural fold was unchanged compared with the
contralateral side. These in vivo results are consistent with the
in vitro findings that anosmin modulates growth factor activities.
Exogenous Anosmin Promotes Cranial Neural
Crest Formation
We next examined whether experimental elevation of anosmin
could promote cranial neural crest formation in vivo. We in-
jected exogenous recombinant anosmin protein into NF regions
and examined for enhanced expression of the key neural crest
marker SNAI2 by whole-mount in situ hybridization. Purified
anosmin protein was injected into HH7+ (2–3 somite-stage)
embryos, and the embryos were allowed to develop untilf each growth factor (GF) alone normalized to 1 RLU. For assaying FGF activity,
(7xOCFRE) were used (G and J). Anosmin enhanced activities of FGF2, FGF4,
d collagen I (5) did not enhance FGF8 in (H). For BMP activity, a C2C12 cell line
ed BMP5 and BMP7 activity (K). In contrast, the ECM proteins fibronectin and
ressing a WNT-specific promoter (TOPflash) was used (I). Anosmin inhibited
as means and SEM. *p < 0.05. **p < 0.01.
nosmin protein- or BSA-soaked beadswere implanted into the cranial region of
on from six to seven embryos each were dissected and examined by western
bryo. Arrowheads indicate enhanced phosphorylated p38 (M) and increased
k) were injected into the cranial region of HH7+ embryos; asterisks in (O) and (P)
) and (R) indicate injection in the middle midbrain region. The embryos were
mount in situ hybridization. Exogenous anosmin-enhanced FGF8 and SNAI2
mbryos (P-P0 and R-R00 0, respectively). Scale bar, 150 mm in (O), (P), (Q), and (R)
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Figure 6. Anosmin Is Required for Cranial Neural Crest Differentia-
tion and Normal Head Formation, and Exogenous Anosmin Alters
Craniofacial Morphology
(A–C0) Whole-mount HNK-1 staining of control-mo- and two independent
anosmin-mo-treated embryos. Electroporation of FITC-tagged mo was per-
formed at HH4+-5, and the embryos were cultured for 26 hr until HH12-13.
Compared with the control embryos, indicated by arrowheads in (A) and (A0),
migrating neural crest cells are severely reduced and head formation is
defective in the anosmin-mo-treated embryos, indicated by arrowheads in (B),
(B0), (C), and (C0). Scale bar, 200 mm.
(D–N) Purified-anosmin-coated or BSA-coated control beads were grafted in
the cranial region at HH9 embryos in ovo, and the eggs were incubated for
3 more days until HH23 or for 8 days until HH35. FGF8 expression was
examined at HH23 (D–I), and alcian blue staining was performed at HH35 to
visualize Meckel’s cartilage (Mc), as shown in (L). Anosmin-treated embryos
showed fusion of first and second BAs or reduced first BA, with loss of focal
FGF8 expression and increased diffuse FGF8 expression (H and I, indicated
by arrowheads). In most anosmin-treated embryos, the size of mouth became
small compared with contralateral side (J and K), and Mc was absent (L,
indicated by arrowheads) or quadrate (q) cartilage was smaller and retro-
articular process was slightly bigger (N, indicated by arrowheads). bb, basi-
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examined for FGF8 and SNAI2 mRNA expression by whole-
mount in situ hybridization. FGF8 expression in the neural
fold was enhanced by this experimental elevation of anosmin
compared with BSA-injected control embryos (Figures 5P and
5P0, 5/5, arrowheads). Combining these gain-of-function find-
ings with the anosmin knockdown results, our experiments
indicate that anosmin regulates FGF8 expression in the neural
fold. Importantly, anosmin overexpression also enhanced
expression of the neural crest marker SNAI2 and resulted in
increased numbers of SNAI2-positive cells in NFs on the in-
jected side (Figures 5R–5R00 0, 7/10, arrowheads). These results
support the conclusion that anosmin promotes cranial neural
crest formation.
Anosmin Is Required for Cranial Neural Crest
Differentiation and Normal Head Formation
If the primary conclusion of this article is correct (i.e., that anos-
min is essential for normal neural crest formation by modulating
growth factors), there should be subsequent major effects on
tissues derived from the neural crest in later-stage embryos.
To evaluate this, mo-treated embryos were cultured for 26 hr
from HH4+-5 to HH12-13. Whole-mount immunostaining was
then performed using the HNK-1 antibody, which recognizes
a cell surface epitope on migrating neural crest cells (Tucker
et al., 1984). In control-mo-treated embryos, wide regions of
migrating neural crest cells were immunostained by the HNK-1
antibody as shown by the brown staining in Figures 6A and 6A0
(arrowheads). However, in anosmin-mo embryos, areas of
HNK-1 immunoreactivity were severely decreased compared
to controls (Figures 6B and 6B0, anosmin-mo A, 5/6, arrowheads;
Figures 6C and 6C0, anosmin-mo B, 5/6, arrows). In addition to
these deficits in neural crest, we also observed defects in head
formation in anosmin-mo embryos compared to controls
(Figures 6B–6C0) with reduced forebrain and eye primordium.
These results indicate that anosmin is necessary for cranial
neural crest cell development and normal craniofacial
morphology.
Excess Anosmin Affects Craniofacial Morphology
Because our gain-of-function experiments indicated that exoge-
nous anosmin can stimulate neural crest formation (Figure 5), we
evaluated whether exogenous anosmin would alter later cranio-
facial development. Beads soaked with purified anosmin or
bovine serum albumin (BSA) as a control were implanted into
cranial regions of HH9 embryos in ovo. We first confirmed
that control BSA beads did not affect cranial neural crest
formation (data not shown, 11/11) and that considerable
anosmin protein remained intact even 24 hr after implantation
(Figure S5A). The embryoswere cultured for 3–8 days to examine
for late effects on craniofacial morphology, specifically branchial
arches (BAs) at 3 days (HH23) and Meckel’s cartilage forma-
tion at 8 days (HH35). In normal embryogenesis, the maxillary
and mandibular processes are formed separately, and both
processes express FGF8 on their edges (Figures 6D–6F,branchial; bh, basihyal; cb, ceratobranchial; eb, epibranchial; ra, retroarticular
process. Scale bar, 250 mm in D–I, 1 mm in J–L, and 500 mm in M and N.
See also Figure S5.
r Inc.
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displayed smaller maxillary and mandibular processes, with
low or absent FGF8 expression at HH23 (Figures 6H and 6I,
4/5, arrowheads). Excess anosmin also resulted in craniofacial
malformations such as small mouth at HH35 (Figures 6J and
6K; 15/38 at 0.5 mg/ml anosmin) compared with 1/17 using
control beads, or 4/14 at 2 mg/ml and 4/9 at 10 mg/ml anosmin
(data not shown). Elevated anosmin inhibited formation of
Meckel’s cartilage (Figure 6L, 6/26, arrowheads) or abnormal
quadrate cartilage and retroarticular process (Figure 6N, 7/26,
arrowheads) according to alcian blue staining; it sometimes
also resulted in ectopic or extra cartilage surrounding the
oral cavity (mouth) and Meckel’s cartilage (Figures S5B–S5D,
5/26, arrowheads). Taken together, our results suggest that
normal levels of anosmin are important for normal craniofacial
morphology.
DISCUSSION
In this study, we discovered strong differential gene expression
of the ECM protein anosmin in the cranial neural crest by
cDNA microarray analysis and qPCR. We found that anosmin
is secreted by the cranial neural crest and established that it
provides autocrine regulation of cranial neural crest formation.
We also demonstrated that anosmin enhances FGF8 activity,
while inhibiting both BMP5 and WNT3a activities. Depleting or
locally enhancing levels of anosmin revealed its crucial role in
neural crest formation, with rescue of anosmin depletion by an
appropriate combination of growth factors. In addition, our
studies suggest a model in which an ECM protein plays a regu-
latory role in generating cranial neural crest cells by positively
and negatively governing growth factor activities during early
embryonic development.
At early stages (HH3-4+) before cranial neural crest formation,
FGF8, BMP4 (but not BMP5), and WNT3a activities are required
for neural crest specification, as well as gastrulation and neural
induction (Streit et al., 2000; Yang et al., 2002; Monsoro-Burq
et al., 2003; Marchant et al., 1998; Garcı´a-Castro et al., 2002).
In this study, we found that BMP5 mRNA was first detectable
at HH7 following neural crest specification and that its expres-
sion was strongly localized to the cranial neural crest. We
confirmed the role of BMP5 in neural crest formation (data not
shown) by injecting recombinant BMP5 protein (0.5–1.0 mM)
into cranial regions of HH6-7 embryos. At HH8-9, this exogenous
BMP5 strongly induced ectopic expression of the neural crest
marker MSX2 (in neural crest, neural plate, and surrounding
tissues such as epidermis and mesenchyme) but strongly
blocked SNAI2 expression in cranial neural crest. These results,
combined with the BMP5 expression pattern, suggest that
appropriate BMP5 activity is involved in normal cranial neural
crest formation.
Depleting anosmin resulted in diminished expression of the
well-studied neural crest formation genes SNAI2, FOXD3 and
SOX9, but not PAX7, and reduced neural crest differentiation.
In contrast, local increases of anosmin promoted neural crest
formation, with late effects on craniofacial morphology. Our
findings establish that anosmin is a regulatory ECM protein
that is involved in growth factor regulation and neural crest
formation but not in neural crest specification.DevelopHow does anosmin function in neural crest/craniofacial
development? It can both regulate gene expression of the key
growth factors FGF8 and BMP5 and directly bind to FGF8,
BMP5, and WNT3a as it governs their activities. A recent review
by Hynes (2009) proposes the idea that highly conserved
domains of ECM molecules are important for governing inter-
actions and matrix-mediated presentation of growth factors to
receptors. In fact, a recent study demonstrates that the ECM
proteins fibrillin 1 and fibrillin 2 can differentially function to
sequester BMP and/or TGF-b to reduce their functional bioavail-
ability (Nistala et al., 2010). Although anosmin can suppress
BMP5 (but not BMP4) andWNT3a activities, it has dual function-
ality in being able to stimulate FGF8 activity. The modulating or
balancing effects of anosmin that we describe affect three
growth factors—FGF, BMP, and WNT—that are key factors in
neural crest formation and craniofacial development (Sauka-
Spengler and Bronner-Fraser, 2008; Trainor et al., 2002; Shige-
tani et al., 2000).
Our in vivo and in vitro experiments suggest that anosmin
functions as an enhancer of FGF signaling by promoting FGF8-
FGFR1 complex formation through direct interaction with
FGF8. Consistent with this idea, anosmin overexpressed in
Chinese hamster ovary (CHO) cells increases FGFR1 accumula-
tion on the cell membrane (Ayari and Soussi-Yanicostas, 2007).
However, contrary to our findings, Hu and colleagues showed
that anosmin suppresses FGFR1 accumulation and its signaling
through direct binding to FGFR1 (Hu et al., 2009). But, similar to
our results, Hu et al. also reported that anosmin binds to pre-
formed FGF2-FGFR1 indirectly and, in turn, activates FGF
signaling (Hu et al., 2009). One important methodological differ-
ence is that we generated our tag-free anosmin using mamma-
lian cells, whereas Hu et al. (2009) used insect cells. Because
insect cells produce different posttranslational protein modifica-
tions, the discrepancy between their results and ours may be
explained by our use of anosmin produced by mammalian
rather than insect cells.
Finally, could anosmin be involved in other early steps of
embryonic development besides cranial neural crest formation?
In this study, we showed that anosmin regulates SNAI2 gene
expression in cranial neural crest formation. However, SNAI1/2
is a key transcription factor involved not only in neural crest
formation but also in regulating epithelial to mesenchymal
transition (EMT) in cancer metastasis and developmental
processes such as gastrulation (Thiery et al., 2009; Yang and
Weinberg, 2008). Prevention of EMT and mesenchymal-to-
epithelial transition (MET) is also crucial for normal embryonic
developmental processes. For example, SOX2 is strongly ex-
pressed in the neural plate and promotes neural tube develop-
ment by repressing SNAI2 expression (Wakamatsu et al.,
2004), SOX3 prevents gastrulation by suppressing SNAI1/2
expression to maintain neural and nonneural ectoderm (Acloque
et al., 2011), and SOX2 and SOX3 expression can be driven by
FGF signaling (Mansukhani et al., 2005; Ciruna and Rossant,
2001; Acloque et al., 2011). Somitogenesis is a well-known
example of MET converting presomitic mesenchymal cells to
epithelial cells (Nakaya et al., 2004). Interestingly, we detected
anosmin mRNA not only in NFs but also in Hensen’s node at
late gastrulation (HH4+-6) and in migrating presomitic mesoderm
before somitogenesis at HH7-9 (Figure 2). Moreover, we findmental Cell 23, 305–316, August 14, 2012 ª2012 Elsevier Inc. 313
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entire neural plate (Figure 2). Since a balance of FGF, BMP,
and WNT control EMT and MET during embryonic development
(Dorey and Amaya, 2010; Heisenberg and Solnica-Krezel, 2008;
Sylvie et al., 2011), it may be interesting to examine potential
roles of anosmin in developmental processes involving transi-
tions to epithelia and mesenchyme, such as gastrulation, neural
tube development, and somitogenesis by regulating SNAI1/2
and SOX2/3.
In summary, our findings provide evidence that an ECM
protein in the cellular microenvironment can both negatively
and positively coordinate regulatory growth factor activities at
temporal and spatial levels to facilitate specific tissue differenti-
ation during embryonic development.
EXPERIMENTAL PROCEDURES
Experimental Animals and RNA Isolation
Fertile chicken eggs were obtained from CBT Farms, Federalsburg, MD, USA,
or Charles River Laboratories, North Franklin, CT, USA, and were incubated
at 38C in a humidified incubator. Embryos were staged according to the
procedures of Hamburger and Hamilton (1951).
NFs and neural plates were dissected from HH stage 8 embryos using tung-
sten needles (Fine Science Tools) in ice-cold Hanks’ balanced salt solution
(HBSS, Invitrogen) supplemented with 1 mM MgCl2, 1 mM CaCl2, and 1 mM
HEPES at pH 7.5. The isolated tissues were dissolved in TRIzol (Invitrogen),
snap frozen in dry ice/ethanol, and then stored at 80C overnight. Total
RNA isolated according to the manufacturer’s protocol was treated with
DNase I (Sigma) at 37C for 30 min.
Whole-Embryo Culture and MO Transfection
HH4+ to 5 embryos were cultured dorsal side down spanning a hole in filter
paper on egg white in a 35 mm culture dish covered by Parafilm as described
previously with minor modifications (Chapman et al., 2001; Y.E., unpublished
data). For electroporation, the embryos were placed into an electroporation
chamber fromUniqueMedical Imada filled with HBSS. Fluorescein isothiocya-
nate (FITC)-labeled mo [Gene Tools, 0.5 to 1 mM morpholino mixed with
5 mg/ml empty pCAGGS plasmid (Momose et al., 1999) in HBSS] were injected
on to the entire cranial neural ectoderm region of the embryos followed by
two square-wave electroporation pulses (10 mV, 25 ms duration separated
by 200 ms) using a CUY21 electroporator (Tokiwa Science). After electropora-
tion, the embryo was placed in the 35mm dish dorsal side down. The embryos
were incubated within amoist glass dish at 38C for 10–11 hr to HH8 or 26 hr to
HH12-13. The antisense mo used were: standard control (50-CCTCTTACC
TCAGTTACAATTTATA-30) and two different oligonucleotides for the chicken
anosmin 50UTR antisense (A: 50-TGCTGCGGGCTGAGCTGCTGCTCGC-30
and B: 50-CAGCTCCGCGCCGCAGAAACTAAAC-30) designed according to
Rugarli et al. (1993).
Anosmin and Other Antibodies
Customanosmin antibodies (HL6158,HL6157, andHL6308; seeSupplemental
Experimental Procedures) were produced (Covance). HL6158 and HL6157
antibodieswere used for immunostaining andwestern blotting. For coimmuno-
precipitation and ELISA, HL6157 andHL6308 antibodies were used. FGF8 and
FGFR1 antibodies were from R&D Systems; and total p38, phospho-p38, total
SMAD1, phospho-SMAD1/5/8, and total ERK1/2, phospho-ERK1/2 antibodies
were from Cell Signaling Technology. HNK-1 and SNAI2 (62.1E6) antibodies
were from the Developmental Studies Hybridoma Bank. Anti-fibronectin anti-
body (R745) was previously described (Cukierman et al., 2001).
In Situ Hybridization and Immunohistochemistry
In situ hybridization and immunohistochemistry on frozen sections and in
whole mounts were performed as described previously (Endo et al., 2002),
with minor modifications as described in Supplemental Experimental
Procedures.314 Developmental Cell 23, 305–316, August 14, 2012 ª2012 ElsevieCell Lines
Mouse melanoma cells (B16-F10, ATCC) and myoblasts (C2C12BRA from
Dr. Daniel Rifkin; Zilberberg et al., 2007) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 mg/ml streptomycin. For anosmin protein purification,
B16-F10 cells were cultured in serumfree, antibioticfree DMEM (see Supple-
mental Experimental Procedures). For generating stable FGF or WNT reporter
cell lines, wild-type mouse myoblasts C2C12 (ATCC) were transfected with an
osteocalcin FGF response element (7xOCFRE) promoter/luciferase reporter
(from Dr. Dwight Towler; Newberry et al., 1996) or TOPflash (Millipore) with
pEF1-Neo (Invitrogen) using Lipofectamine 2000 (Invitrogen). The cells were
selected in 600 mg/ml G418 (Mediatech) for 2 weeks, and they were transferred
to G418-free medium 1 day before initiating experiments.
Growth Factors and Receptor-Binding Assay
Recombinant mouse or human FGF2,4, 8, human BMP2, 4, 5, 7, and
mouse WNT3a were from R&D Systems. For the receptor binding assay,
recombinant FGF8 was preincubated with/without anosmin protein for 1 hr
at room temperature in 0.1% BSA/Binding buffer (Invitrogen), and then
FGFR1c-Fc (R&D Systems) was added for an additional hour. FGF8 bound
to its receptor was detected by western blotting using anti-FGF8 or anti-
FGFR1 antibodies (R&D Systems) after Dynabead protein G (Invitrogen)
precipitation of the receptor or anosmin by HL6157 or HL6308 antibodies
following the manufacturer’s protocol.
Luciferase Reporter Assay
C2C12-7xOCFRE, -BRA, or -TOPflash cells were seeded in 96-well culture
plates (Corning) at 4 3 103 cells/well. The cells were cultured in DMEM with
10%FBS and antibiotics. After 24 hr, themediumwas replacedwith serumfree
0.1% BSA (Sigma)/DMEM containing recombinant proteins (see previous
paragraph) and purified extracellular matrix proteins as described for each
experiment. After 18 hr (6 hr for the WNT assay), the cells were washed twice
with PBS, and cells were lysed using 50 ml 13 Passive Lysis Buffer (Promega).
Lysates were assayed for luciferase activity using the Luciferase Assay
System from Promega and a Mithras LB 940 microplate reader (Berthold
Technologies).
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The microarray data are deposited in GEO under series accession number
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